InBio and Beckman Coulter Life Sciences Announce Strategic Partnership to Advance Food Allergy Research with Next-Generation Basophil Activation Testing

Click here to view as a PDF.

Charlottesville, Virginia, July 2025 — InBio, a global leader in high-quality, purified allergen
proteins, and Beckman Coulter Life Sciences, a Danaher company and a global leader in
laboratory automation and innovation, are collaborating to enhance the performance of basophil
activation tests (BAT) for food allergy research. The collaboration integrates InBio’s Food
Protein Standards and purified allergens with the Next-Generation Basophil Activation Test
(BAT) platform from Beckman Coulter Life Sciences.

InBio’s Food Protein Standards and purified allergen components are potent, biologically
active proteins derived from foods such as peanut, egg, milk, tree nuts, and shellfish. These
reagents are a critical component for BAT tests, and are validated for immunological
consistency, ensuring reproducibility in high-sensitivity assays.

“Allergens are the molecular engines of BAT testing” said Dr. Martin Chapman, CEO and
Founder of InBio. “This partnership combines InBio’s expertise in food allergen manufacturing
and engineering with next-gen BAT technology from Beckman Coulter Life Sciences. Together,
we can provide a robust, standardized approach for food allergy with greater accuracy and
reproducibility which will advance food allergic research.”

Launched in the spring of 2025, the Next-Generation BAT* by Beckman Coulter Life Sciences
is a research use only breakthrough in functional allergy testing that offers researchers a
powerful tool to assess allergic sensitization and reactivity with greater precision. Leveraging
advanced flow cytometry and automation to measure basophil activation in response to allergen
exposure, the Next-Generation BAT is an in vitro alternative to oral food challenges. The
integration of InBio’s food proteins ensures consistency in allergen stimulation, reducing
variability and improving test interpretation.

“This collaboration with InBio represents another crucial step forward in evolving and
innovating food allergy research to deliver results faster and significantly safer to vulnerable
participants,” said Jean-Marc Busnel, PhD, Principal Investigator and Senior Staff Research
Scientist at Beckman Coulter Life Sciences. “Removing the complexities of oral food challenges
opens new doors in food allergy research that can unleash pioneering new discoveries. Our
collaboration puts this new innovation in reach to more laboratories around the world.”

BAT are functional assays measuring basophil activation in response to specific allergens or
other stimuli. By leveraging dry technology to overcome traditional BAT challenges,
standardization is enabled with conjugated antibodies and allergens pre-mixed and dried down
together in a single tube, thereby enabling streamlined centrifugation-free BAT protocols
consisting of only four pipetting steps. The Next-Generation BAT powered by InBio allergens
can test for multiple allergens at once through a blood draw — saving hours of food testing and
exposure to potentially harmful reactions.

*For Research Use Only. Not for use in diagnostic procedures.

About InBio
InBio, with locations in Charlottesville, VA USA, and Cardiff, Wales, specializes in
manufacturing high-quality, purified allergens and test kits for allergy diagnostics, environmental
monitoring, and immunological research. With a commitment to precision and standardization,
InBio’s allergen molecules are used globally to support cutting-edge allergy science. Research
made real! Learn more at www.inbio.com.

About Beckman Coulter Life Sciences
Time is the most critical facet in the laboratory today:  time to get life-saving therapies to
patients faster; reclaiming time by automating tedious manual workflows; and saving time
otherwise spent addressing erroneous or complex results.

At Beckman Coulter Life Sciences, A Danaher company, we are partners in time. We accelerate
answers to critical questions through the power of efficiency, saving hours from some workflows
and delivering reliable results in centrifugation, flow cytometry, genomic solutions, particle
analysis/counters, and liquid handlers.

We develop innovations for scientists by scientists, with many of our 3,300+ global colleagues
coming from the laboratory with a deep understanding of today’s challenges and complexities.
We’re passionate about translating science in partnership with our customers, and our
customizable, accessible and sustainable solutions empower them with intuitive workflow
efficiencies.

Time and again customers put their trust in us, with 400,000+ of our built-to-last products
currently delivering results in labs worldwide – all backed by our dependable service and
application experts offering educational insights and tailored support.

It’s all part of our time-tested approach since 1935 to bring meaningful innovations at the speed
of life—and we’re just beginning. Working together, let’s advance human health for a better
tomorrow! Get to know us by clicking here and by following us on LinkedIn.

Beckman Coulter Life Sciences is proud to be part of Danaher. Visit www.danaher.com to learn
more about Danaher, a leading life sciences and diagnostics innovator committed to accelerating
the power of science and technology to improve human health.

Contacts
InBio: Beattie Sturgill, VP of Business Development bsturgill@inbio.com
Beckman Coulter Life Sciences: Matt McCutcheon, Global External Communications Manager,
mmccutcheon@beckman.com